| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
03-07-2009, 09:27 PM
|
#1 | |||
|
||||
|
In Remembrance
|
Teva's Azilect Use Dramatically Increases In Second-Line Therapy For The Treatment Of Parkinson's Disease
05 Mar 2009 Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report. Most of this increased patient share was driven by growth in the use of Teva's Azilect which is attributed to physicians' growing comfort with the drug and data attesting to its possible neuroprotective (disease-modifying) effects. http://www.medicalnewstoday.com/arti...php?nfid=52345
__________________
with much love, lou_lou . . by . , on Flickr pd documentary - part 2 and 3 . . Resolve to be tender with the young, compassionate with the aged, sympathetic with the striving, and tolerant with the weak and the wrong. Sometime in your life you will have been all of these. |
|||
|
 Reply With Quote
|
| "Thanks for this!" says: | olsen (03-07-2009) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Trial Results Show Teva's AZILECT(R) 1 mg Tablets Slow Progression of PD | Parkinson's Disease | |||
Teva's Azilect Use Dramatically Increases In Second-Line Therapy For The Treatment PD
Linear Mode
